US FDA Serves One Antacid/Analgesic Question For AdComm, Opens Tap On Hangover Discussion
This article was originally published in The Pink Sheet
Executive Summary
Presentations at the US nonprescription drugs/drug safety joint advisory committee meeting will come from Bayer, marketer of the OTC brand synonymous with antacid/aspirin formulations, Alka-Seltzer, and from a firm that markets Blowfish, a caffeine/aspirin OTC indicated as a hangover remedy.
You may also be interested in...
Alka-Seltzer Antacid Will 'Plop, Plop Fizz, Fizz' Without Aspirin
In advance of a US FDA advisory panel meeting on the safety of OTC monograph antacid/aspirin products, Bayer is removing aspirin from its pioneering Alka-Seltzer effervescent indigestion products. Bayer's Andre Schmidt talks about the safety advantages and consumer trends that helped spur the change.
Safety Review For Upset Stomach, Hangover OTCs Reconsiders Science
The US Nonprescription Drugs and Drug Safety and Risk Management advisory committees will discuss the safety of using OTC analgesic combination products for upset stomach and hangover even though Drug Facts labels already warn about the risk of serious bleeding.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”